

SPE RESPONSE FOR CERTIFICATE OF CORRECTION

Paper No.: _____

DATE

: 4/5/06

TO SPE OF

: ART UNIT

11652 11656

SUBJECT

: Request for Certificate of Correction for Appl. No.:

09/832929 Patent No.: 6926898

Please respond to this request for a certificate of correction within 7 days.

Please review the requested changes/corrections as shown in the COCIN document(s) in the IFW application image. No new matter should be introduced, nor should the scope or meaning of the claims be changed.

Please complete the response (see below) and forward the completed response to scanning using document code **COCX**.

H. R. L.

Certificates of Correction Branch

703-308-9390 ext. _____

Thank You For Your Assistance

The request for issuing the above-identified correction(s) is hereby:

Note your decision on the appropriate box.

☒ Approved

All changes apply.

☐ Approved in Part

Specify below which changes do not apply.

☐ Denied

State the reasons for denial below.

Comments: _____

KATHLEEN M. KERR, PH.D.
SUPERVISORY PATENT EXAMINER

Kathleen

SPE

11656

Art Unit

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. 6,926,898

Page 1 of 35

APPLICATION NO.: 09/832,929

ISSUE DATE: August 9, 2005

INVENTOR(S): Craig A. Rosen and William A. Haseltine

It is hereby certified that an error or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Under item (60) (Related U.S. Application Data) of the title page, delete the text beginning with "Provisional application No. 60/256,931" to and ending "provisional application No. 60/229,358, filed on Apr. 12, 2000."

Under item (56) (References Cited) of the title page and under U.S. PATENT DOCUMENTS beginning on page 1, insert:

--	2003-0022308 A1	1/2003	Fleer et al.
	2003-0036170 A1	2/2003	Fleer et al.
	2003-0036171 A1	2/2003	Fleer et al.
	2003-0036172 A1	2/2003	Fleer et al.
	2003-0054554 A1	3/2003	Becquart et al.
	2003-0082747 A1	5/2003	Fleer et al.
	2003-0104578 A1	10/2001	Ballance
	2004-0010134 A1	4/2001	Rosen et al.
	09/832,501	4/2001	Ballance et al.
	09/833,041	4/2001	Rosen et al.
	09/833,111	4/2001	Rosen et al.
	09/833,117	4/2001	Rosen et al.
	09/833,118	4/2001	Rosen et al.
	10/702,536	11/2003	Fleer et al.
	10/702,636	11/2003	Fleer et al. --

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413

JAN 04 2006

Under item (56) (References Cited) of the title page and under OTHER PUBLICATIONS beginning on page 1, insert:

- Larsson, M., et al., "Role of Annexins in Endocytosis of Antigens in Immature Human Dendritic Cells," *Immunology* 92:501-511 (1997).
- Latta, M. et al., "Synthesis and Purification of Mature Human Serum Albumin From *E. Coli*," *Bio/Technology* 5:1309-1314 (1987).
- Latta, M., et al., "Tryptophan Promoter Derivatives on Multicopy Plasmids: A Comparative Analysis of Expression Potentials in *Escherichia coli*," *DNA and Cell Biology* 9:129-137 (1990).
- Lawn, R.M., et al., "The Sequence of Human Serum Albumin cDNA and its Expression in *E. coli*," *Nucleic Acids Research* 9:6103-6113 (1981).
- Le Bras, M., et al., "Epidemiologie et Clinique des Maladies Tropicales D'importation," *La Revue de Medicine Interne* 13:205-210 (1992), with English translation.
- Leblois, H., et al., "Stable Transduction of Actively Dividing Cells via a Novel Adenoviral/Episomal Vector," *Molecular Therapy* 1:314-322 (2000).
- Lee, C-H., et al., "Sodium Pertechnetate Tc99m Antral Scan in the Diagnosis of Retained Gastric Antrum," *Arch. Surg.* 119: 309-311 (1984).
- Lee, C-L., et al., "Preparation and Characterization of Polyethylene-Glycol-Modified Salmon Calcitonins," *Pharmaceutical Development and Technology*, 4(2): 269-275 (1999).
- Lee, W-C., et al., "Identification and Characterization of a Nuclear Localization Sequence-Binding Protein in Yeast," *Proc. Natl. Acad. Sci. USA* 86:8808-8812 (1989).
- Lee, Y-H., et al., "Comparison of Effective Renal Plasma Flow (ERPF) and Endogenous Creatinine Clearance (Ccr) in Evaluation of the Differential Kidney Function: An in Vivo Study," *Chin. Med. J. (Taipei)* 49:147-152 (1992).
- Lei, H-Y., et al., "An Antigen-specific Hypersensitivity Which Does Not Fit Into Traditional Classification of Hypersensitivity," *The Journal of Immunology* 143:432-438 (1989).
- Levitt, D., et al., "Toxicity of Perfluorinated Fatty-Acids for Human and Murine B Cell Lines," *Toxicology and Applied Pharmacology* 86:1-11 (1986).

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413

JAN 04 2006

Lew D.B., et al., "Mitogenic Effect of Lysosomal Hydrolases on Bovine Tracheal Myocytes in Culture," *The Journal of Clinical Investigation* 88:1969-1975 (1991).

Lewis, C., et al., "Is Sexual Dysfunctoin in Hypertensive Women Uncommon or Understudied?" *American Jour of Hypertension*," 11:733-735 (1998). --

Under item (57) (ABSTRACT) of the title page, "disordrs" should read --disorders--.

In the Specification

Col. 143, line 26, delete "As exhibited in Table 2, most", and insert --Most--.

Col. 143, line 31, delete "Table 2".

In the Claims

Col. 340, line 40, delete "an".

Col. 340, line 47, delete "an".

In the Sequence Listing

Delete the Sequence Listing beginning in Col. 299, beginning with the text "<160> NUMBER OF SEQ ID NOS: 72" to and ending "<400> SEQUENCE: 72

Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
1 5 10 15"

in Col. 340 and insert the following Sequence Listing:

<160> NUMBER OF SEQ ID NOS: 82

<210> 1

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221> primer_bind

<223> primer useful to clone human growth hormone cDNA

<400> 1

cccaagaatt cccttatcca ggc

23

<210> 2

<211> 33

<212> DNA

<213> Artificial Sequence

<220>

<221> primer_bind

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413

<223> primer useful to clone human growth hormone cDNA

<400> 2

gggaagctta gaagccacag gatccctcca cag

33

<210> 3

<211> 16

<212> DNA

<213> Artificial Sequence

<220>

<221> misc_structure

<223> synthetic oligonucleotide used to join DNA fragments with non-cohesive ends.

<400> 3

gataaagatt cccaac

16

<210> 4

<211> 17

<212> DNA

<213> Artificial Sequence

<220>

<221> misc_structure

<223> synthetic oligonucleotide used to join DNA fragments with non-cohesive ends.

<400> 4

aattgttggg aatcttt

17

<210> 5

<211> 17

<212> DNA

<213> Artificial Sequence

<220>

<221> misc_structure

<223> synthetic oligonucleotide used to join DNA fragments with non-cohesive ends.

<400> 5

ttaggttat tccaac

17

<210> 6

<211> 18

<212> DNA

<213> Artificial Sequence

<220>

<221> misc_structure

<223> synthetic oligonucleotide used to join DNA fragments with non-cohesive ends.

<400> 6

aattgttggg aataagcc

18

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413

JAN 04 2006

<400> 10
 ctcttgtgtg catcgaagcc acag 24

 <210> 11
 <211> 30
 <212> DNA
 <213> Artificial Sequence
 <220>
 <221> misc_structure
 <223> synthetic oligonucleotide used to join DNA fragments with non-cohesive ends.

 <400> 11
 tgtggaagag cctcagaatt tattcccaac 30

 <210> 12
 <211> 31
 <212> DNA
 <213> Artificial Sequence
 <220>
 <221> misc_structure
 <223> synthetic oligonucleotide used to join DNA fragments with non-cohesive ends.

 <400> 12
 aattgttggg aataaattct gaggtctctc c 31

 <210> 13
 <211> 47
 <212> DNA
 <213> Artificial Sequence
 <220>
 <221> misc_structure
 <223> synthetic oligonucleotide used to join DNA fragments with non-cohesive ends.

 <400> 13
 ttaggcttag gtggcgggtg atccggcggt ggtggatctt tcccaac 47

 <210> 14
 <211> 48
 <212> DNA
 <213> Artificial Sequence
 <220>
 <221> misc_structure
 <223> synthetic oligonucleotide used to join DNA fragments with non-cohesive ends.

 <400> 14
 aattgttggg aaagatccac caccgccgga tccaccgcca cctaagcc 48

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,
 Garrett & Dunner, L.L.P.
 901 New York Avenue, N.W.
 Washington, D.C. 20001-4413

JAN 04 2006

```

<210> 15
<211> 62
<212> DNA
<213> Artificial Sequence
<220>
<221> misc_structure
<223> synthetic oligonucleotide used to join DNA
fragments with non-cohesive ends.

<400> 15
ttaggcttag gcggtggtgg atctggtggc ggcggtatcg gtggcggtgg atccttccca 60
ac 62

<210> 16
<211> 63
<212> DNA
<213> Artificial Sequence
<220>
<221> misc_structure
<223> synthetic oligonucleotide used to join DNA
fragments with non-cohesive ends.

<400> 16
aattgttggg aaggatccac cgccaccaga tccgcgcga ccagatccac caccgcctaa 60
gcc 63

<210> 17
<211> 1782
<212> DNA
<213> Homo sapiens
<220>
<221> CDS
<222> (1) .. (1755)

<400> 17
gat gca cac aag agt gag gtt gct cat cgg ttt aaa gat ttg gga gaa 48
Asp Ala His Lys Ser Glu Val Ala His Arg Phe Lys Asp Leu Gly Glu
1 5 10 15

gaa aat ttc aaa gcc ttg gtg ttg att gcc ttt gct cag tat ctt cag 96
Glu Asn Phe Lys Ala Leu Val Leu Ile Ala Phe Ala Gln Tyr Leu Gln
20 25 30

cag tgt cca ttt gaa gat cat gta aaa tta gtg aat gaa gta act gaa 144
Gln Cys Pro Phe Glu Asp His Val Lys Leu Val Asn Glu Val Thr Glu
35 40 45

ttt gca aaa aca tgt gtt gct gat gag tca gct gaa aat tgt gac aaa 192
Phe Ala Lys Thr Cys Val Ala Asp Glu Ser Ala Glu Asn Cys Asp Lys
50 55 60

```

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413

JAN 04 2006

tca ctt cat acc ctt ttt gga gac aaa tta tgc aca gtt gca act ctt	240
Ser Leu His Thr Leu Phe Gly Asp Lys Leu Cys Thr Val Ala Thr Leu	
65 70 75 80	
cgt gaa acc tat ggt gaa atg gct gac tgc tgt gca aaa caa gaa cct	288
Arg Glu Thr Tyr Gly Glu Met Ala Asp Cys Cys Ala Lys Gln Glu Pro	
85 90 95	
gag aga aat gaa tgc ttc ttg caa cac aaa gat gac aac cca aac ctc	336
Glu Arg Asn Glu Cys Phe Leu Gln His Lys Asp Asp Asn Pro Asn Leu	
100 105 110	
ccc cga ttg gtg aga cca gag gtt gat gtg atg tgc act gct ttt cat	384
Pro Arg Leu Val Arg Pro Glu Val Asp Val Met Cys Thr Ala Phe His	
115 120 125	
gac aat gaa gag aca ttt ttg aaa aaa tac tta tat gaa att gcc aga	432
Asp Asn Glu Glu Thr Phe Leu Lys Lys Tyr Leu Tyr Glu Ile Ala Arg	
130 135 140	
aga cat cct tac ttt tat gcc ccg gaa ctc ctt ttc ttt gct aaa agg	480
Arg His Pro Tyr Phe Tyr Ala Pro Glu Leu Leu Phe Phe Ala Lys Arg	
145 150 155 160	
tat aaa gct gct ttt aca gaa tgt tgc caa gct gct gat aaa gct gcc	528
Tyr Lys Ala Ala Phe Thr Glu Cys Cys Gln Ala Ala Asp Lys Ala Ala	
165 170 175	
tgc ctg ttg cca aag ctc gat gaa ctt cgg gat gaa ggg aag gct tcg	576
Cys Leu Leu Pro Lys Leu Asp Glu Leu Arg Asp Glu Gly Lys Ala Ser	
180 185 190	
tct gcc aaa cag aga ctc aaa tgt gcc agt ctc caa aaa ttt gga gaa	624
Ser Ala Lys Gln Arg Leu Lys Cys Ala Ser Leu Gln Lys Phe Gly Glu	
195 200 205	
aga gct ttc aaa gca tgg gca gtg gct cgc ctg agc cag aga ttt ccc	672
Arg Ala Phe Lys Ala Trp Ala Val Ala Arg Leu Ser Gln Arg Phe Pro	
210 215 220	
aaa gct gag ttt gca gaa gtt tcc aag tta gtg aca gat ctt acc aaa	720
Lys Ala Glu Phe Ala Glu Val Ser Lys Leu Val Thr Asp Leu Thr Lys	
225 230 235 240	
gtc cac acg gaa tgc tgc cat gga gat ctg ctt gaa tgt gct gat gac	768
Val His Thr Glu Cys Cys His Gly Asp Leu Leu Glu Cys Ala Asp Asp	
245 250 255	
agg gcg gac ctt gcc aag tat atc tgt gaa aat cag gat tcg atc tcc	816
Arg Ala Asp Leu Ala Lys Tyr Ile Cys Glu Asn Gln Asp Ser Ile Ser	
260 265 270	

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413

JAN 04 2006

agt aaa ctg aag gaa tgc tgt gaa aaa cct ctg ttg gaa aaa tcc cac	864
Ser Lys Leu Lys Glu Cys Cys Glu Lys Pro Leu Leu Glu Lys Ser His	
275 280 285	
tgc att gcc gaa gtg gaa aat gat gag atg cct gct gac ttg cct tca	912
Cys Ile Ala Glu Val Glu Asn Asp Glu Met Pro Ala Asp Leu Pro Ser	
290 295 300	
tta gct gct gat ttt gtt gaa agt aag gat gtt tgc aaa aac tat gct	960
Leu Ala Ala Asp Phe Val Glu Ser Lys Asp Val Cys Lys Asn Tyr Ala	
305 310 315 320	
gag gca aag gat gtc ttc ctg ggc atg ttt ttg tat gaa tat gca aga	1008
Glu Ala Lys Asp Val Phe Leu Gly Met Phe Leu Tyr Glu Tyr Ala Arg	
325 330 335	
agg cat cct gat tac tct gtc gtg ctg ctg ctg aga ctt gcc aag aca	1056
Arg His Pro Asp Tyr Ser Val Val Leu Leu Leu Arg Leu Ala Lys Thr	
340 345 350	
tat gaa acc act cta gag aag tgc tgt gcc gct gca gat cct cat gaa	1104
Tyr Glu Thr Thr Leu Glu Lys Cys Cys Ala Ala Ala Asp Pro His Glu	
355 360 365	
tgc tat gcc aaa gtg ttc gat gaa ttt aaa cct ctt gtg gaa gag cct	1152
Cys Tyr Ala Lys Val Phe Asp Glu Phe Lys Pro Leu Val Glu Glu Pro	
370 375 380	
cag aat tta atc aaa caa aac tgt gag ctt ttt gag cag ctt gga gag	1200
Gln Asn Leu Ile Lys Gln Asn Cys Glu Leu Phe Glu Gln Leu Gly Glu	
385 390 395 400	
tac aaa ttc cag aat gcg cta tta gtt cgt tac acc aag aaa gta ccc	1248
Tyr Lys Phe Gln Asn Ala Leu Leu Val Arg Tyr Thr Lys Lys Val Pro	
405 410 415	
caa gtg tca act cca act ctt gta gag gtc tca aga aac cta gga aaa	1296
Gln Val Ser Thr Pro Thr Leu Val Glu Val Ser Arg Asn Leu Gly Lys	
420 425 430	
gtg ggc agc aaa tgt tgt aaa cat cct gaa gca aaa aga atg ccc tgt	1344
Val Gly Ser Lys Cys Cys Lys His Pro Glu Ala Lys Arg Met Pro Cys	
435 440 445	
gca gaa gac tat cta tcc gtg gtc ctg aac cag tta tgt gtg ttg cat	1392
Ala Glu Asp Tyr Leu Ser Val Val Leu Asn Gln Leu Cys Val Leu His	
450 455 460	
gag aaa acg cca gta agt gac aga gtc aca aaa tgc tgc aca gag tcc	1440
Glu Lys Thr Pro Val Ser Asp Arg Val Thr Lys Cys Cys Thr Glu Ser	
465 470 475 480	

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413

JAN 04 2006

```

ttg gtg aac agg cga cca tgc ttt tca gct ctg gaa gtc gat gaa aca 1488
Leu Val Asn Arg Arg Pro Cys Phe Ser Ala Leu Glu Val Asp Glu Thr
                     485                     490                     495

tac gtt ccc aaa gag ttt aat gct gaa aca ttc acc ttc cat gca gat 1536
Tyr Val Pro Lys Glu Phe Asn Ala Glu Thr Phe Thr Phe His Ala Asp
                     500                     505                     510

ata tgc aca ctt tct gag aag gag aga caa atc aag aaa caa act gca 1584
Ile Cys Thr Leu Ser Glu Lys Glu Arg Gln Ile Lys Lys Gln Thr Ala
                     515                     520                     525

ctt gtt gag ctt gtg aaa cac aag ccc aag gca aca aaa gag caa ctg 1632
Leu Val Glu Leu Val Lys His Lys Pro Lys Ala Thr Lys Glu Gln Leu
                     530                     535                     540

aaa gct gtt atg gat gat ttc gca gct ttt gta gag aag tgc tgc aag 1680
Lys Ala Val Met Asp Asp Phe Ala Ala Phe Val Glu Lys Cys Cys Lys
545                     550                     555                     560

gct gac gat aag gag acc tgc ttt gcc gag gag ggt aaa aaa ctt gtt 1728
Ala Asp Asp Lys Glu Thr Cys Phe Ala Glu Glu Gly Lys Lys Leu Val
                     565                     570                     575

gct gca agt caa gct gcc tta ggc tta taacatctac atttaaaagc atctcag 1782
Ala Ala Ser Gln Ala Ala Leu Gly Leu
                     580                     585

<210> 18
<211> 585
<212> PRT
<213> Homo Sapiens

<400> 18
Asp Ala His Lys Ser Glu Val Ala His Arg Phe Lys Asp Leu Gly Glu
 1             5             10             15

Glu Asn Phe Lys Ala Leu Val Leu Ile Ala Phe Ala Gln Tyr Leu Gln
 20             25             30

Gln Cys Pro Phe Glu Asp His Val Lys Leu Val Asn Glu Val Thr Glu
 35             40             45

Phe Ala Lys Thr Cys Val Ala Asp Glu Ser Ala Glu Asn Cys Asp Lys
 50             55             60

Ser Leu His Thr Leu Phe Gly Asp Lys Leu Cys Thr Val Ala Thr Leu
 65             70             75             80

Arg Glu Thr Tyr Gly Glu Met Ala Asp Cys Cys Ala Lys Gln Glu Pro
 85             90             95

```

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413

JAN 04 2006

Glu Arg Asn Glu Cys Phe Leu Gln His Lys Asp Asp Asn Pro Asn Leu	100	105	110
Pro Arg Leu Val Arg Pro Glu Val Asp Val Met Cys Thr Ala Phe His	115	120	125
Asp Asn Glu Glu Thr Phe Leu Lys Lys Tyr Leu Tyr Glu Ile Ala Arg	130	135	140
Arg His Pro Tyr Phe Tyr Ala Pro Glu Leu Leu Phe Phe Ala Lys Arg	145	150	155
Tyr Lys Ala Ala Phe Thr Glu Cys Cys Gln Ala Ala Asp Lys Ala Ala	165	170	175
Cys Leu Leu Pro Lys Leu Asp Glu Leu Arg Asp Glu Gly Lys Ala Ser	180	185	190
Ser Ala Lys Gln Arg Leu Lys Cys Ala Ser Leu Gln Lys Phe Gly Glu	195	200	205
Arg Ala Phe Lys Ala Trp Ala Val Ala Arg Leu Ser Gln Arg Phe Pro	210	215	220
Lys Ala Glu Phe Ala Glu Val Ser Lys Leu Val Thr Asp Leu Thr Lys	225	230	235
Val His Thr Glu Cys Cys His Gly Asp Leu Leu Glu Cys Ala Asp Asp	245	250	255
Arg Ala Asp Leu Ala Lys Tyr Ile Cys Glu Asn Gln Asp Ser Ile Ser	260	265	270
Ser Lys Leu Lys Glu Cys Cys Glu Lys Pro Leu Leu Glu Lys Ser His	275	280	285
Cys Ile Ala Glu Val Glu Asn Asp Glu Met Pro Ala Asp Leu Pro Ser	290	295	300
Leu Ala Ala Asp Phe Val Glu Ser Lys Asp Val Cys Lys Asn Tyr Ala	305	310	315
Glu Ala Lys Asp Val Phe Leu Gly Met Phe Leu Tyr Glu Tyr Ala Arg	325	330	335
Arg His Pro Asp Tyr Ser Val Val Leu Leu Leu Arg Leu Ala Lys Thr	340	345	350
Tyr Glu Thr Thr Leu Glu Lys Cys Cys Ala Ala Ala Asp Pro His Glu	355	360	365

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413

JAN 04 2006

Cys Tyr Ala Lys Val Phe Asp Glu Phe Lys Pro Leu Val Glu Glu Pro
 370 375 380
 Gln Asn Leu Ile Lys Gln Asn Cys Glu Leu Phe Glu Gln Leu Gly Glu
 385 390 395 400
 Tyr Lys Phe Gln Asn Ala Leu Leu Val Arg Tyr Thr Lys Lys Val Pro
 405 410 415
 Gln Val Ser Thr Pro Thr Leu Val Glu Val Ser Arg Asn Leu Gly Lys
 420 425 430
 Val Gly Ser Lys Cys Cys Lys His Pro Glu Ala Lys Arg Met Pro Cys
 435 440 445
 Ala Glu Asp Tyr Leu Ser Val Val Leu Asn Gln Leu Cys Val Leu His
 450 455 460
 Glu Lys Thr Pro Val Ser Asp Arg Val Thr Lys Cys Cys Thr Glu Ser
 465 470 475 480
 Leu Val Asn Arg Arg Pro Cys Phe Ser Ala Leu Glu Val Asp Glu Thr
 485 490 495
 Tyr Val Pro Lys Glu Phe Asn Ala Glu Thr Phe Thr Phe His Ala Asp
 500 505 510
 Ile Cys Thr Leu Ser Glu Lys Glu Arg Gln Ile Lys Lys Gln Thr Ala
 515 520 525
 Leu Val Glu Leu Val Lys His Lys Pro Lys Ala Thr Lys Glu Gln Leu
 530 535 540
 Lys Ala Val Met Asp Asp Phe Ala Ala Phe Val Glu Lys Cys Cys Lys
 545 550 555 560
 Ala Asp Asp Lys Glu Thr Cys Phe Ala Glu Glu Gly Lys Lys Leu Val
 565 570 575
 Ala Ala Ser Gln Ala Ala Leu Gly Leu
 580 585

<210> 19

<211> 58

<212> DNA

<213> Artificial Sequence

<220>

<221> primer_bind

<223> primer used to generate XhoI and ClaI site in pPPC0006

<400> 19

gcctcgagaa aagagatgca cacaagagtg aggttgctca tcgatttaaa gatttggg 58

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,
 Garrett & Dunner, L.L.P.
 901 New York Avenue, N.W.
 Washington, D.C. 20001-4413

JAN 04 2006

<210> 20
 <211> 59
 <212> DNA
 <213> Artificial Sequence
 <220>
 <221> primer_bind
 <223> primer used in generation XhoI and ClaI site in pPPC0006

 <400> 20
 aatcgatgag caacctcact cttgtgtgca tctcttttct cgaggctcct ggaataagc 59

 <210> 21
 <211> 24
 <212> DNA
 <213> Artificial Sequence
 <220>
 <221> primer_bind
 <223> primer used in generation XhoI and ClaI site in pPPC0006

 <400> 21
 taaaaactta agagtccaat tagc 24

 <210> 22
 <211> 29
 <212> DNA
 <213> Artificial Sequence
 <220>
 <221> primer_bind
 <223> primer used in generation XhoI and ClaI site in pPPC0006

 <400> 22
 cacttctcta gagtggtttc atatgtctt 29

 <210> 23
 <211> 60
 <212> DNA
 <213> Artificial Sequence
 <220>
 <221> Misc_Structure
 <223> Synthetic oligonucleotide used to alter restriction sites in pPPC0007

 <400> 23
 aagctgcctt aggcttataa taaggcgcgc cggccggccg tttaaactaa gcttaattct 60

 <210> 24
 <211> 60
 <212> DNA
 <213> Artificial Sequence
 <220>
 <221> Misc_Structure
 <223> Synthetic oligonucleotide used to alter restriction sites in pPPC0007

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,
 Garrett & Dunner, L.L.P.
 901 New York Avenue, N.W.
 Washington, D.C. 20001-4413

JAN 04 2006

<400> 24
 agaattaagc ttagtttaaa cggccggccg gcgcgcctta ttataagcct aaggcagctt 60

 <210> 25
 <211> 32
 <212> DNA
 <213> Artificial Sequence
 <220>
 <221> primer_bind
 <223> forward primer useful for generation of albumin fusion protein in which
 the albumin moiety is N-terminal of the Therapeutic Protein
 <220>
 <221> misc feature
 <222> (18)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (19)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (20)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (21)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (22)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (23)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (24)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (25)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (26)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (27)
 <223> n equals a,t,g, or c
 <220>

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,
 Garrett & Dunner, L.L.P.
 901 New York Avenue, N.W.
 Washington, D.C. 20001-4413

JAN 04 2006

```

<221> misc feature
<222> (28)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (29)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (30)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (31)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (32)
<223> n equals a,t,g, or c

<400> 25
aagctgcctt aggcttannn nnnnnnnnnn nn
32

<210> 26
<211> 51
<212> DNA
<213> Artificial Sequence
<220>
<221> primer_bind
<223> reverse primer useful for generation of albumin fusion protein in which
the albumin moiety is N-terminal of the Therapeutic Protein
<220>
<221> misc feature
<222> (37)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (38)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (39)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (40)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (41)
<223> n equals a,t,g, or c
<220>

```

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413

JAN 04 2006


```

<221> misc feature
<222> (42)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (43)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (44)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (45)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (46)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (47)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (48)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (49)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (50)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (51)
<223> n equals a,t,g, or c

<400> 26
gcgcgcgttt aaacggccgg ccggcgcgcc ttattannnn nnnnnnnnnn n
51

<210> 27
<211> 33
<212> DNA
<213> Artificial Sequence
<220>
<223> forward primer useful for generation of albumin fusion protein in which
the albumin moiety is c-terminal of the Therapeutic Protein
<220>
<221> misc feature

```

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413

JAN 04 2006

<222> (19)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (20)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (21)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (22)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (23)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (24)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (25)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (26)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (27)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (28)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (29)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (30)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (31)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,
 Garrett & Dunner, L.L.P.
 901 New York Avenue, N.W.
 Washington, D.C. 20001-4413

JAN 04 2006

<222> (32)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (33)
 <223> n equals a,t,g, or c

 <400> 27
 aggagcgtcg acaaaagann nnnnnnnnnn nnn 33

 <210> 28
 <211> 52
 <212> DNA
 <213> Artificial Sequence
 <220>
 <221> primer_bind
 <223> reverse primer useful for generation of albumin fusion protein in which
 the albumin moiety is c-terminal of the Therapeutic Protein
 <220>
 <221> misc feature
 <222> (38)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (39)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (40)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (41)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (42)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (43)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (44)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (45)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,
 Garrett & Dunner, L.L.P.
 901 New York Avenue, N.W.
 Washington, D.C. 20001-4413

JAN 04 2006

```

<222> (46)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (47)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (48)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (49)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (50)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (51)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (52)
<223> n equals a,t,g, or c

<400> 28
ctttaaatcg atgagcaacc tcaactottgt gtgcacnann nnnnnnnnnn nn          52

<210> 29
<211> 24
<212> PRT
<213> Artificial Sequence
<220>
<221> signal
<223> signal peptide of natural human serum albumin protein

<400> 29
Met Lys Trp Val Ser Phe Ile Ser Leu Leu Phe Leu Phe Ser Ser Ala
  1               5               10               15

Tyr Ser Arg Ser Leu Asp Lys Arg
      20

<210> 30
<211> 114
<212> DNA
<213> Artificial Sequence
<220>
<221> primer_bind
<223> forward primer useful for generation of PC4:HSA albumin fusion VECTOR

```

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413

JAN 04 2006

```

<220>
<221> misc_feature
<222> (5)..(10)
<223> BamHI restriction site
<220>
<221> misc_feature
<222> (11)..(16)
<223> Hind III restriction site
<220>
<221> misc_feature
<222> (17)..(27)
<223> Kozak sequence
<220>
<221> misc_feature
<222> (25)..(97)
<223> cds natural signal sequence of human serum albumin
<220>
<221> misc_feature
<222> (75)..(81)
<223> XhoI restriction site
<220>
<221> misc_feature
<222> (98)..(114)
<223> cds first six amino acids of human serum albumin

<400> 30
tcagggatcc aagcttccgc caccatgaag tgggtaacct ttatttcctc tctttttctc 60

tttagctcgg cttactcgag ggggtgtgtt cgtcgagatg cacacaagag tgag      114

<210> 31
<211> 43
<212> DNA
<213> Artificial Sequence
<220>
<221> primer_bind
<223> reverse primer useful for generation of PC4:HSA albumin fusion VECTOR
<220>
<221> misc_feature
<222> (6)..(11)
<223> Asp718 restriction site
<220>
<221> misc_feature
<222> (12)..(17)
<223> EcoRI restriction site
<220>
<221> misc_feature
<222> (15)..(17)
<223> reverse complement of stop codon
<220>
<221> misc_feature
<222> (18)..(25)

```

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413

JAN 04 2005

<223> AscI restriction site
 <220>
 <221> misc_feature
 <222> (18)..(43)
 <223> reverse complement of DNA sequence encoding last 9 amino acids

 <400> 31
 gcagcggtac cgaattcggc ggcgccttata agcctaaggc agc 43

 <210> 32
 <211> 46
 <212> DNA
 <213> Artificial Sequence
 <220>
 <221> primer_bind
 <223> forward primer useful for inserting Therapeutic protein into pC4:HSA
 vector
 <220>
 <221> misc feature
 <222> (29)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (30)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (31)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (32)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (33)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (34)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (35)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (36)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (37)

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,
 Garrett & Dunner, L.L.P.
 901 New York Avenue, N.W.
 Washington, D.C. 20001-4413

JAN 04 2006

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (38)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (39)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (40)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (41)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (42)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (43)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (44)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (45)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (46)

<223> n equals a,t,g, or c

<400> 32

cgcgcgctcg aggggtgtgt ttcgtcgann nnnnnnnnnn nnnnnn

46

<210> 33

<211> 55

<212> DNA

<213> Artificial Sequence

<220>

<221> primer_bind

<223> reverse primer useful for inserting Therapeutic protein into pC4:HSA vector

<220>

<221> misc feature

<222> (38)

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413

JAN 04 2006

<223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (39)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (40)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (41)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (42)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (43)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (44)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (45)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (46)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (47)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (48)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (49)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (50)
 <223> n equals a,t,g, or c
 <220>
 <221> misc feature
 <222> (51)

MAILING ADDRESS OF SENDER

Finnegan, Henderson, Farabow,
 Garrett & Dunner, L.L.P.
 901 New York Avenue, N.W.
 Washington, D.C. 20001-4413

U.S. Patent No. 6,926,898

JAN 04 2006


```

<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (52)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (53)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (54)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (55)
<223> n equals a,t,g, or c

<400> 33
agtcccatcg atgagcaacc tcactcttgt gtgcatcnnn nnnnnnnnnn nnnnn      55

<210> 34
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<221> signal
<223> Stanniocalcin signal peptide

<400> 34
Met Leu Gln Asn Ser Ala Val Leu Leu Leu Leu Val Ile Ser Ala Ser Ala
  1             5             10             15

<210> 35
<211> 22
<212> PRT
<213> Artificial Sequence
<220>
<221> signal
<223> Synthetic signal peptide

<400> 35
Met Pro Thr Trp Ala Trp Trp Leu Phe Leu Val Leu Leu Leu Ala Leu
  1             5             10             15

Trp Ala Pro Ala Arg Gly
      20

<210> 36
<211> 23
<212> DNA
<213> Artificial Sequence
<220>

```

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413

JAN 04 2006

```

<221>primer_bind
<223>Degenerate VH forward primer useful for amplifying human VH domains

<400> 36
caggtgcagc tgggtgcagtc tgg                                23

<210> 37
<211> 23
<212> DNA
<213> Artificial Sequence
<220>
<221>primer_bind
<223>Degenerate VH forward primer useful for amplifying human VH domains

<400> 37
caggtcaact taaggagtc tgg                                23

<210> 38
<211> 23
<212> DNA
<213> Artificial Sequence
<220>
<221>primer_bind
<223>Degenerate VH forward primer useful for amplifying human VH domains

<400> 38
gaggtgcagc tgggtggagtc tgg                                23

<210> 39
<211> 23
<212> DNA
<213> Artificial Sequence
<220>
<221>primer_bind
<223>Degenerate VH forward primer useful for amplifying human VH domains

<400> 39
caggtgcagc tgcaggagtc ggg                                23

<210> 40
<211> 23
<212> DNA
<213> Artificial Sequence
<220>
<221>primer_bind
<223>Degenerate VH forward primer useful for amplifying human VH domains

<400> 40
gaggtgcagc tgttgcagtc tgc                                23

<210> 41
<211> 23

```

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413

JAN 04 2006

<212> DNA
 <213> Artificial Sequence
 <220>
 <221>primer_bind
 <223>Degenerate VH forward primer useful for amplifying human VH domains

 <400> 41
 caggtacagc tgcagcagtc agg 23

 <210> 42
 <211> 24
 <212> DNA
 <213> Artificial Sequence
 <220>
 <221>primer_bind
 <223>Degenerate JH reverse primer useful for amplifying human VH domains

 <400> 42
 tgaggagacg gtgaccaggg tgcc 24

 <210> 43
 <211> 24
 <212> DNA
 <213> Artificial Sequence
 <220>
 <221>primer_bind
 <223>Degenerate JH reverse primer useful for amplifying human VH domains

 <400> 43
 tgaagagacg gtgaccattg tccc 24

 <210> 44
 <211> 24
 <212> DNA
 <213> Artificial Sequence
 <220>
 <221>primer_bind
 <223>Degenerate JH reverse primer useful for amplifying human VH domains

 <400> 44
 tgaggagacg gtgaccaggg ttcc 24

 <210> 45
 <211> 24
 <212> DNA
 <213> Artificial Sequence
 <220>
 <221>primer_bind
 <223>Degenerate JH reverse primer useful for amplifying human VH domains

 <400> 45
 tgaggagacg gtgaccgtgg tccc 24

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,
 Garrett & Dunner, L.L.P.
 901 New York Avenue, N.W.
 Washington, D.C. 20001-4413

JAN 04 2006

```

<210> 46
<211> 23
<212> DNA
<213> Artificial Sequence
<220>
<221>primer_bind
<223>Degenerate Vkappa forward primer useful for amplifying human VL domains

<400> 46
gacatccaga tgacccagtc tcc 23

<210> 47
<211> 23
<212> DNA
<213> Artificial Sequence
<220>
<221>primer_bind
<223>Degenerate Vkappa forward primer useful for amplifying human VL domains

<400> 47
gatgtgtga tgactcagtc tcc 23

<210> 48
<211> 23
<212> DNA
<213> Artificial Sequence
<220>
<221>primer_bind
<223>Degenerate Vkappa forward primer useful for amplifying human VL domains

<400> 48
gatattgtga tgactcagtc tcc 23

<210> 49
<211> 23
<212> DNA
<213> Artificial Sequence
<220>
<221>primer_bind
<223>Degenerate Vkappa forward primer useful for amplifying human VL domains

<400> 49
gaaattgtgt tgacgcagtc tcc 23

<210> 50
<211> 23
<212> DNA
<213> Artificial Sequence
<220>
<221>primer_bind
<223>Degenerate Vkappa forward primer useful for amplifying human VL domains

```

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413

JAN 04 2006

<400> 50
 gacatcgtga tgacccagtc tcc 23

 <210> 51
 <211> 23
 <212> DNA
 <213> Artificial Sequence
 <220>
 <221>primer_bind
 <223>Degenerate Vkappa forward primer useful for amplifying human VL domains

 <400> 51
 gaaacgacac tcacgcagtc tcc 23

 <210> 52
 <211> 23
 <212> DNA
 <213> Artificial Sequence
 <220>
 <221>primer_bind
 <223>Degenerate Vkappa forward primer useful for amplifying human VL domains

 <400> 52
 gaaattgtgc tgactcagtc tcc 23

 <210> 53
 <211> 23
 <212> DNA
 <213> Artificial Sequence
 <220>
 <221>primer_bind
 <223>Degenerate Vlamba forward primer useful for amplifying human VL domains

 <400> 53
 cagtctgtgt tgacgcagcc gcc 23

 <210> 54
 <211> 23
 <212> DNA
 <213> Artificial Sequence
 <220>
 <221>primer_bind
 <223>Degenerate Vlamba forward primer useful for amplifying human VL domains

 <400> 54
 cagtctgccc tgactcagcc tgc 23

 <210> 55
 <211> 23
 <212> DNA
 <213> Artificial Sequence
 <220>

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,
 Garrett & Dunner, L.L.P.
 901 New York Avenue, N.W.
 Washington, D.C. 20001-4413

JAN 04 2006

```

<221>primer_bind
<223>Degenerate Vlambda forward primer useful for amplifying human VL domains

<400> 55
tcctatgtgc tgactcagcc acc                                23

<210> 56
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221>primer_bind
<223>Degenerate Vlambda forward primer useful for amplifying human VL domains

<400> 56
tcttctgagc tgactcagga ccc                                23

<210> 57
<211> 23
<212> DNA
<213> Artificial Sequence
<220>
<221>primer_bind
<223>Degenerate Vlambda forward primer useful for amplifying human VL domains

<400> 57
cacgttatac tgactcaacc gcc                                23

<210> 58
<211> 23
<212> DNA
<213> Artificial Sequence
<220>
<221>primer_bind
<223>Degenerate Vlambda forward primer useful for amplifying human VL domains

<400> 58
caggctgtgc tcactcagcc gtc                                23

<210> 59
<211> 23
<212> DNA
<213> Artificial Sequence
<220>
<221>primer_bind
<223>Degenerate Vlambda forward primer useful for amplifying human VL domains

<400> 59
aatattatgc tgactcagcc cca                                23

```

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413

JAN 04 2006

```

<210> 60
<211> 24
<212> DNA
<213> Artificial Sequence
<220>
<221>primer_bind
<223>Degenerate Jkappa reverse primer useful for amplifying human VL domains

<400> 60
acgtttgatt tccaccttgg tccc                24

<210> 61
<211> 24
<212> DNA
<213> Artificial Sequence
<220>
<221>primer_bind
<223>Degenerate Jkappa reverse primer useful for amplifying human VL domains

<400> 61
acgtttgatc tccagcttgg tccc                24

<210> 62
<211> 24
<212> DNA
<213> Artificial Sequence
<220>
<221>primer_bind
<223>Degenerate Jkappa reverse primer useful for amplifying human VL domains

<400> 62
acgtttgata tccactttgg tccc                24

<210> 63
<211> 24
<212> DNA
<213> Artificial Sequence
<220>
<221>primer_bind
<223>Degenerate Jkappa reverse primer useful for amplifying human VL domains

<400> 63
acgtttgatc tccaccttgg tccc                24

<210> 64
<211> 24
<212> DNA
<213> Artificial Sequence
<220>
<221>primer_bind
<223>Degenerate Jkappa reverse primer useful for amplifying human VL domains

```

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413

JAN 04 2006

<400> 64	
acgtttaatc tccagtcgtg tccc	24
<210> 65	
<211> 23	
<212> DNA	
<213> Artificial Sequence	
<220>	
<221>primer_bind	
<223>Degenerate Jlambda reverse primer useful for amplifying human VL domains	
<400> 65	
cagtctgtgt tgacgcagcc gcc	23
<210> 66	
<211> 23	
<212> DNA	
<213> Artificial Sequence	
<220>	
<221>primer_bind	
<223>Degenerate Jlambda reverse primer useful for amplifying human VL domains	
<400> 66	
cagtctgccc tgactcagcc tgc	23
<210> 67	
<211> 23	
<212> DNA	
<213> Artificial Sequence	
<220>	
<221>primer_bind	
<223>Degenerate Jlambda reverse primer useful for amplifying human VL domains	
<400> 67	
tcctatgtgc tgactcagcc acc	23
<210> 68	
<211> 23	
<212> DNA	
<213> Artificial Sequence	
<220>	
<221>primer_bind	
<223>Degenerate Jlambda reverse primer useful for amplifying human VL domains	
<400> 68	
tcttctgagc tgactcagga ccc	23
<210> 69	
<211> 23	
<212> DNA	
<213> Artificial Sequence	
<220>	

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413

JAN 04 2006


```

<221>primer_bind
<223>Degenerate Jlambda reverse primer useful for amplifying human VL domains

<400> 69
cacgttatac tgactcaacc gcc                23

<210> 70
<211> 23
<212> DNA
<213> Artificial Sequence
<220>
<221>primer_bind
<223>Degenerate Jlambda reverse primer useful for amplifying human VL domains

<400> 70
caggctgtgc tcactcagcc gtc                23

<210> 71
<211> 23
<212> DNA
<213> Artificial Sequence
<220>
<221>primer_bind
<223>Degenerate Jlambda reverse primer useful for amplifying human VL domains

<400> 71
aattttatgc tgactcagcc cca                23

<210> 72
<211> 15
<212> PRT
<213> Artificial Sequence
<220>
<221>turn
<223>Linker peptide that may be used to join VH and VL domains in an scFv.

<400> 72
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
  1             5             10             15

<210> 73
<211> 733
<212> DNA
<213> Homo sapiens

<400> 73
gggatccgga gcccaaactct tctgacaaaa ctcacacatg cccaccgtgc ccagcacctg      60
aattegaggg tgcaccgtca gtcttctctt tccccccaaa acccaaggac accctcatga      120
tctcccggaac tcctgaggtc acatgcgtgg tgggtggacgt aagccacgaa gaccctgagg      180

```

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413

JAN 04 2006

tcaagttcaa ctggtacgtg gacggcgtgg aggtgcataa tgccaagaca aagccgcggg	240
aggagcagta caacagcacg taccgtgtgg tcagcgctct caccgtcctg caccaggact	300
ggctgaatgg caaggagtac aagtgcaagg tctccaacaa agccctccca acccccatcg	360
agaaaaccat ctccaaagcc aaagggcagc cccgagaacc acaggtgtac accctgcccc	420
catccccgga tgagctgacc aagaaccagg tcagcctgac ctgcctggtc aaaggcttct	480
atccaagcga catcgccgtg gagtgggaga gcaatgggca gccggagaac aactacaaga	540
ccacgcctcc cgtgctggac tccgacggct ccttcttct ctacagcaag ctcaccgtgg	600
acaagagcag gtggcagcag gggaacgtct tctcatgctc cgtgatgcat gaggtctctgc	660
acaaccacta cacgcagaag agcctctccc tgtctccggg taaatgagtg cgacggccgc	720
gactctagag gat	733

<210> 74
 <211> 5
 <212> PRT
 <213> Artificial sequence
 <220>
 <221> misc_structure
 <223> membrane proximal motif of class 1 cytokine receptors
 <220>
 <221> misc_feature
 <222> (3)
 <223> Xaa equals any

<400> 74
 Trp Ser Xaa Trp Ser
 1 5

<210> 75
 <211> 86
 <212> DNA
 <213> Artificial Sequence
 <220>
 <221> primer_bind
 <223> forward primer useful for generation of a synthetic gamma activation site (GAS) containing promoter element

<400> 75	
gcgcctcgag atttccccga aatctagatt tccccgaaat gatttccccg aaatgatttc	60
cccgaatat ctgccatctc aattag	86

<210> 76
 <211> 27

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,
 Garrett & Dunner, L.L.P.
 901 New York Avenue, N.W.
 Washington, D.C. 20001-4413

JAN 04 2006

<212> DNA
 <213> Artificial Sequence
 <220>
 <221> primer_bind
 <223> reverse primer useful for generation of a synthetic gamma activation site (GAS) containing promoter element

<400> 76
 gcggcaagct ttttgcaaag cctaggc 27

<210> 77
 <211> 271
 <212> DNA
 <213> Artificial Sequence
 <220>
 <221> misc_feature
 <223> Synthetic GAS-SV40 promoter sequence

<400> 77
 ctcgagattt ccccgaatc tagatttccc cgaaatgatt tccccgaaat gatttccccg 60
 aaatatctgc catctcaatt agtcagcaac catagtcccc cccctaactc cgcccatccc 120
 gccctaact ccgccagtt ccgccattc tccgccccat ggctgactaa ttttttttat 180
 ttatgcagag gccgaggccg cctcggcctc tgagctattc cagaagtagt gaggaggctt 240
 ttttggaggc ctaggctttt gcaaaaagct t 271

<210> 78
 <211> 32
 <212> DNA
 <213> Artificial Sequence
 <220>
 <221> primer_bind
 <223> primer useful for generation of a EGR/SEAP reporter construct

<400> 78
 gcgctcgagg gatgacagcg atagaacccc gg 32

<210> 79
 <211> 31
 <212> DNA
 <213> Artificial Sequence
 <220>
 <221> primer_bind
 <223> primer useful for generation of a EGR/SEAP reporter construct

<400> 79
 gcgaagcttc gcgactcccc ggatccgcct c 31

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,
 Garrett & Dunner, L.L.P.
 901 New York Avenue, N.W.
 Washington, D.C. 20001-4413

JAN 04 2006

<210> 80
 <211> 12
 <212> DNA
 <213> Artificial Sequence
 <220>
 <221> misc_binding
 <223> NF-KB binding site

<400> 80
 ggggactttc cc 12

<210> 81
 <211> 73
 <212> DNA
 <213> Artificial Sequence
 <220>
 <221> primer_bind
 <223> forward primer useful for generation of a vector containing the NF-KB promoter element

<400> 81
 gcggcctcga ggggactttc ccggggactt tccggggact ttccgggact ttccatcctg 60
 ccattctcaat tag 73

<210> 82
 <211> 256
 <212> DNA
 <213> Artificial Sequence
 <220>
 <221> misc_feature
 <223> Synthetic NF-KB/SV40 promoter

<400> 82
 ctcgagggga ctttcccggg gactttccgg ggactttccg ggactttcca tctgccatct 60
 caattagtca gcaaccatag tcccgccct aactccgcc atcccgcctc taactccgcc 120
 cagttccgcc cattctccgc cccatggctg actaattttt tttatttatg cagaggccga 180
 ggccgcctcg gcctctgagc tattccagaa gtagtgagga ggcttttttg gaggcctagg 240
 cttttgcaaa aagctt 256

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,
 Garrett & Dunner, L.L.P.
 901 New York Avenue, N.W.
 Washington, D.C. 20001-4413

JAN 04 2006